Schering-Plough files asthma combination in Europe
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMEA) has agreed to review Schering-Plough's centralised EU application for approval to market a fixed-dose inhaled combination of its corticosteroid Asmanex (mometasone furoate) and the long-acting beta-2 agonist formoterol fumarate (Novartis's Foradil) for the maintenance treatment of asthma in patients aged 12 years and older.